August 30th 2023
In an interview Targeted Oncology, Christina Fotopoulou, MD, PhD, discussed the background and results of 3 studies for patients with ovarian cancer.
August 28th 2023
The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.
August 4th 2023
In an interview with Targeted Oncology, Barbara Buttin, MD, discussed important ovarian cancer research for which results were presented during the 2023 ASCO Annual Meeting.
There was no difference in the risk of disease progression or death outcomes noted between patients with ovarian cancer treated with batiraxcept and paclitaxel vs batiraxcept alone in the AXLerate-OC trial.
August 2nd 2023
Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.
Willmott Reviews Updates From PARP Inhibitor Maintenance Trials for Ovarian Cancer
During a Targeted Oncology™ Clinical Case Forum™ event, Lyndsay Willmott, MD, discussed the data supporting the use of PARP inhibitors as primary maintenance therapy for patients with ovarian cancer.
Maintenance Therapy With Niraparib Prolongs PFS in Ovarian Cancer
Niraparib as a monotherapy is supported as standard of care for a broad patient population with advanced ovarian cancer after first-line platinum-based chemotherapy.
Updated FDA Approvals for PARP Inhibitors in Ovarian Cancer
An expert gynecologic oncologist comments on recent revisions to FDA-approved indications for PARP inhibitors in the treatment of ovarian cancer.
Recent Long-Term Data on PARP Inhibitors in Ovarian Cancer
Leslie Randall, MD, MAS, reviews recent long-term data on PARP inhibitors in the treatment of ovarian cancer.
Managing Adverse Events from PARP Inhibitors in Ovarian Cancer
Clinical insights on how to manage adverse events for patients with ovarian cancer who are receiving PARP inhibitors.
Treatment Considerations for PARP Inhibitors in Ovarian Cancer
An expert on ovarian cancer discusses factors that influence PARP inhibitor selection, when to initiate maintenance therapy, and how to counsel patients on PARP inhibitors.
Maintenance Therapy Treatment Landscape for BRCA-Mutated Advanced Ovarian Cancer
Leslie Randall, MD, MAS, reviews the available treatment options for BRCA-mutated advanced ovarian cancer.
Guideline Recommendations for Molecular Testing in Ovarian Cancer
An overview of guideline recommendations for molecular testing in ovarian cancer.
Patient Profile: A 55-Year-Old with BRCA-Mutated Ovarian Cancer
Leslie Randall, MD, MAS, presents the case of a 55-year-old woman with BRCA-mutated ovarian cancer and provides her initial impressions.
RAMP 201 Findings Support Use of Avutometinib Plus Defactinib in Recurrent LGSOC
The combination of avutometinib with defactinib elicited high activity in patients with recurrent low-grade serous ovarian cancer, according to data from RAMP 201.
Niraparib Maintenance Therapy Induces Antitumor Activity in Advanced Ovarian Cancer
The use of maintenance niraparib therapy led to clinically meaningful improvement in progression-free survival, compared with placebo, in patients with newly diagnosed, advanced ovarian cancer.
Real-World Study Supports Second-Line Maintenance Therapy With Niraparib in Recurrent Ovarian Cancer
Second-line maintenance therapy with niraparib improved overall survival in a BRCA gene wild-type population with recurrent ovarian cancer.
Mirvetuximab Soravtansine Results from MIRASOL Deemed Practice-Changing for Frα+ Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.
Maintenance Bevacizumab Combo Extends PFS in Ovarian Cancer
Phase 3 DUO-O study results reveal a promising strategy for patients with HRD-negative advanced ovarian cancer.
FDA Grants FTD to ACR-368 for Platinum-Resistant Ovarian and Endometrial Cancer
ACR-368 generated deep and durable responses across several phase 2 studies. The agent has now been granted fast track designations for patients with platinum-resistant ovarian cancer and endometrial cancer.
World Ovarian Cancer Day: Biomarkers Shape Treatment Decisions for Ovarian Cancer
In an interview with Targeted Oncology for World Ovarian Cancer Day, Natalie Godbee, DO, discussed the current state of treatment for advanced ovarian cancer and how oncologists can get the best outcomes for their patients.
Mirvetuximab Soravtansine Continues to Outperform Chemo in FRα-High Ovarian Cancer
Impressive efficacy data and consistent safety data continue to be seen with mirvetuximab soravtansine for the treatment of patients with platinum-resistant ovarian cancer, according to data from the confirmatory MIRASOL trial.
Conditional PFS Rates Support Benefit of Niraparib in Ovarian Cancer
Treatment with niraparib elicited durable conditional progression-free survival rates vs placebo in patients with ovarian cancer whose tumors were homologous recombination deficient.
DiSilvestro Looks at PARP Inhibition as First-Line Maintenance Therapy in Advanced Ovarian Cancer
During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the key trials supporting the use of PARP inhibitor maintenance therapy for patients with advanced ovarian cancer.
Phase 1 Trial of IDE161 Doses First Patient With Advanced Solid Tumors
The safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE161, a potent, selective, small-molecule inhibitor of PARG, is being evaluated in a phase 1 clinical trial for advanced solid tumors.
Phase 1b Study of NXP800 Initiates for Patients With Ovarian Cancer
Using the recommended doses of 50 and 70 mg per day from a phase 1a trial of NXP800, the agent will be further evaluated in patients with platinum-resistant, ARID1a-mutated ovarian cancer.
Phase 3 Trial Further Examines Maintenance Mirvetuximab Soravtansine in Ovarian Cancer
Mirvetuximab soravtansine is being assessed in combination with bevacizumab as a treatment for patients with folate receptor-alpha-positive recurrent platinum-sensitive ovarian cancer.
Substantial Benefit Shown With Botensilimab/Balstilimab in Ovarian Cancer
In an interview with Targeted Oncology, Bruno Bockorny, MD, discussed background and key takeaways from the phase 1 C-800 study.
Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations
In the phase 3 DUO-O study, combing 5 targeted and chemotherapy agents for the treatment of newly diagnosed, advanced, high-grade epithelial ovarian cancer with or without BRCA mutations has shown to extend progression-free survival.
Final Analysis of Niraparib Does Not Show Significant OS Benefit in Recurrent Ovarian Cancer
In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.
Carolina Frailty Index Score Validated in Ovarian Cancer
Carolina Frailty Index Score can effectively assess frailty status in women with ovarian cancer.
Maintenance Niraparib Dose Modification Does Not Affect PFS in Ovarian Cancer
Among patients with newly diagnosed, advanced ovarian cancer, dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival.
Dual Checkpoint Blockade With Neoadjuvant Chemo Shows Benefit in Ovarian Cancer
The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.
HRQOL Not Affected by Cytoreductive Surgery Plus HIPEC in Ovarian Cancer
According to Vadim Gushchin, MD, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of how it may impact a patient’s health-related quality of life.
PAOLA-1 Shows Benefit from Olaparib After Bevacizumab in Ovarian Cancer
During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of bevacizumab followed by olaparib maintenance in patients with advanced ovarian cancer.
This is the third of 3 articles based on this event.
2 Clarke Drive Cranbury, NJ 08512